Here’s why $HIMS $NVO Partnership triggered a 40% move🟢💊 For HIMS, this removes a major legal regulatory risk that was previously priced in, Novo had an ongoing suit with Hims, HIMS stopped selling the oral solution likely due to a patent infringement from Novo, removing this